The pandemic continues to keep us on our toes - infection rates are once again rising sharply. To counteract the pandemic, a new drug against Corona is currently being tested. In an interview on Radio Paradiso 98.2's program "Natürlich Gesund", Dr. Holger Zimmermann, CEO of AiCuris Anti-infective Cures AG, and Renée Werner of emovis talk about the mode of action and possible applications of the new drug, as well as about the current course of the study in the company's own COVID Trial Unit at emovis - for which they are currently looking for participants who have tested positive.
You can listen to the german-speaking interview here: Radio Paradiso.
Last year the IKK BB Berlin company run had to be cancelled due to corona. This year, fortunately, it was able to take place - albeit, of course under the appropriate conditions.
On the evening of September 15th, the time had come: a 5.5-kilometer course was waiting to be mastered. Along with many other companies, emovis had once again sent a few employees into the race. They dressed up accordingly, of course, wearing our team name Staffelokokken on their chest!
The starting point was the Brandenburg Gate. From there, the race went in a circle along Ebertstraße, Tiergartenstraße, and Großer Stern then back to Straße des 17. Juni. The rainy weather did not dampen the mood – as you can see and hear in this video where you’ll see Mariella Brzoska.
Many thanks to all emovis runners for their participation - especially Daniel Schulz, who organized the whole thing so well!
Seven companies, one mission: to advance the education of clinical research: As of July 12, 2021, we and other companies (including BAYER AG and CHARITÉ RESEARCH ORGANISATION GmbH) "Förderverein zum Internationalen Tag der klinischen Forschung e.V." are a registered association. Read more in the following press release!
What is the best way to counter a pandemic? With combined forces! That is why we are pleased to announce that from now on emovis and CRS Clinical Research Services Mannheim GmbH will be jointly dedicated to COVID-19-specific projects:
In March 2021, emovis will be 20 years old, and rightly so: Various goals that we have achieved in the last two decades speak for themselves. By founding the company in March 2001, Dr. med. Bettina Bergtholdt set the ball rolling for all our successes.
In recent years, we have conducted more than 250 clinical studies, and in the process, gained experience with more than 120 different indications. In total, we have recruited more than 7,000 study participants and satisfied more than 100 clients to date.
We at emovis know no standstill: Since our foundation, we have grown steadily, so that we now have a wide range of services at our disposal. Join us in reviewing our biggest milestones so far:
In 2008, we established our sleep laboratory, a high-quality, medically equipped, as well as cozy examination place, where we monitor our patients' sleep. This was followed in 2012 by the establishment of our Homecare Visits service, which enables certain impaired patients to participate in clinical trials. With this new service we were able to successfully complete over 100 projects. In a cancer study, for example, we made 1,500 homecare visits within 20 months. In 2014, our CEO, Dr. med. Bergtholdt, founded the service camovis together with Ms. Kurth: The Flying Study Nurses support study centers that need highly qualified staff during peak periods. In 2018, we added our Early Phase Unit, with a focus on psychiatric indications. Two years later, in 2020, we founded our Patient Access Group, which allows us to recruit study participants quickly and efficiently throughout the DACH region. And now, in 2021, our latest achievement: the COVID Trial Unit – an innovative service that enables us to conduct safe clinical trials with covid-19 patients.
Among all the many clinical studies we have conducted so far, some proved to be particularly successful: In 2008, we were able to recruit 844 study participants within 8 months for a vaccination study against herpes zoster. In 2010, we enrolled 371 participants in 24 months for a smoking cessation study. In 2017, we succeeded in recruiting 239 patients within 15 months for a study on insomnia. In 2019, we were able to enroll 45 study participants for a study on genital herpes within 8 months, reaching 180 percent of our target. In 2020, we conducted a vaccination study on tetanus, diphtheria and pertussis: In phase II of the study, we were able to recruit 153 study participants within 4 weeks and achieved 153 percent of our target. In phase III, we enrolled 345 patients within 3 weeks and achieved 138 percent of our target.
Our successes, however, are not only evident in our study-related numbers but also in external assessments: In 2013, emovis was subjected to an FDA inspection. The result: absolutely no objections. In 2015, we received the DEN INNOVATION AWARD for our Homecare Visits service. In 2016, we received the Clinical Research Site Award. Of course, we are delighted to receive such awards – they drive us forward even more. However, grateful study participants whom we have been able to help in clinical trials have always been and will continue to be the main motivation for our work.
Our stone continues to roll – we look forward to the next 20 years of emovis!
Over 100 years ago a vaccine was developed as a protection against the respiratory disease tuberculosis. It is now being tested whether this vaccine can also help with Covid-19. An infection with the corona virus can have serious consequences for high-risk patients. With this vaccine the course of the disease can be alleviated. The advantage of this vaccine: The vaccine does not target the virus directly but rather the strengthening of the immune system. Therefore, the vaccine does not lose its effects even if the viral strain changes. First results of this study can be expected by summer 2021. We are proud to be involved in this fascinating project.
One thing becomes particularly clear in the times of COVID-19: how important clinical trials are.
Research institutes all over the world are conducting research on a vaccine to protect the population from the new virus. But regardless of the current situation, companies in the field of clinical research make an important contribution every day developing therapy options and the medications of the future.
Patients participating simultaneously at different studies currently became a frequent problem in clinical trials. Mistakes and falsely results are the consequence. Therefore, many leading Research Centres in Germany joined the global database for Verified Clinical Trials (VCT). The objective is to prevent protocol violations, patients double participating and to ensure the data quality.
It is now easier to identify and prevent patients participating at different study sites at once. Without the usage of a tool such as VCT is the recognition of over registration in clinical trials nearly impossible. There are several research locations in the immediate vicinity. Therefore, becoming problematic when study participants visit several study sites at once. Verified Clinical Trials is used to prevent over registration to ensure the safety during the whole study period.
Our Executive Manager Dr. Bettina Bergtholdt: “The safety of our patients is the primary goal in all clinical trials. It is our aim, to offer innovative treatment possibilities and at the same time to ensure their safety. Joining the database of Verified Clinical Trials will definitely aid us to archive this goal.”
The benefits of in-home nursing in clinical trials are numerous and they differ between stakeholder sponsors, CROs, sites and patients. But at what point do you decide to include homecare in your project?
Direct-to-Patient projects are complex and require collaboration and planning. Deliveries must often be precisely timed to coincide with the patient's availability of nurse home visits. Immediate proof that temperature control has been maintained is required prior to administering medication. Patient samples are packages for delivery to testing labs.
All of this requires the highest level of training and professionalism, discover insights on home care visits in clinical trials as we take you through the journey from destination to enrolment.
Key Learning Points:
The event is free of charge, lunch and coffee will be served at the event. Ute Bertelsmann and Rebeca Gonzalez Vicedo of emovis GmbH and emovis Homecare Visits will be speakers at the seminar.
Sign up here
This year’s PCT Europe is held in Amsterdam from Nov. 28 – 29. emovis will be in attendance and Dr. Bettina Bergtholdt can be experienced within the framework of the congress multiple times with her expertise. 1st as a panelist on the panel "Recruitment from the perspective of an investigative Site – pitfalls and strategies" as well as in a workshop on Nov 27, addressing the topic "Briefing Day A: The Outsourcing and Partnering Forum".
emovis will not only attend the professional congress"Next Generation Nicotine Delivery Conference 2017" on Nov. 14 -15, you may encounter the Managing Director emovis-,Dr. Bettina Bergtholdt as a panelist. Together with Dr. Alexander (Sascha) Nussbaum from Philip Morris she will share her expertise in the subject "The role of clinical trials in driving the success of new nicotine products".
München, 23 November 2017. Prior to its 25th Symposium, the Federal Association of Contract Research Organisations (BVMA e.V.) in Germany announced the election of the new Executive Board. Martin Krauss was elected to serve as President. Martin Krauss is co-founder and Managing Director of FGK Clinical Research GmbH and has been a member of the Board before. Ralf Freese from CTC North GmbH & Co. KG was appointed Vice President. Also joining the Board is Dr Yvonne Rollinger, Managing Director of OmniComm Europe GmbH.
Dr Dagmar Chase, Managing Director of Clinrex GmbH, a Board member since 1993 and President since 2001, as well as Dr Michael Gierend, Managing Director of medicomp GmbH, Board member since 1997 and Vice President for 16 years, were no longer standing for re-election.
Dr Dagmar Chase about the new appointments: “The BVMA is an important stakeholder of clinical research in Germany. It was very important for us, the previous Board members, to have a smooth transition to the new executive leadership, and this can now be accomplished. A new generation will now take over leadership, but will still be supported by previous Board members who continue their membership in the association. The new Board with Martin Krauss as President is well-positioned and well-prepared to continue the Association’s successful work.”
“The new Board is looking forward to take on its duties and new challenges”, the new President Martin Krauss commented on his appointment. “Clinical research faces constant changes - digitalization is just one example - and new developments come up more and more frequently. A close cooperation and exchange of information between members, representatives from industry, regulatory bodies, ethics committees, and other stakeholders are essential to keep up with these growing demands. The BMVA will also focus in the future on keeping Germany attractive for clinical research and strengthening clinical research for the patient’s benefit. I would like to express gratitude to Dagmar Chase, who has been the BVMA’s president for many years, and has made the BVMA an important stakeholder.”
The BVMA was founded in July 1991 as a representative body for CROs (Contract Research Organisations) based in German-speaking countries. The current 41 members are service providers in research and development of pharmaceuticals and medical devices. Throughout Germany, the BVMA represents about 4000 employees in clinical research. In the past years, the association has successfully strived to be represented in relevant regulatory bodies. As a co-founder and member of the European umbrella organisation (European CRO Federation, EUCROF), the BVMA also ensures its international position. The current President of the EUCROF, Dr Martine Dehlinger-Kremer, is a BVMA member. The BVMA is based in München, Germany.
Every year in November, the BVMA organises a symposium, which became (with more than 300 participants) one of the most important conferences in clinical research. At the same time, the symposium has served for the last 25 years as an established platform for the exchange of information between stakeholders in this field.